Botulinum toxin a possible therapeutic option for rosacea
Research indicates the neuromodulator may affect a neurogenic component that influences vascular dysfunction, inflammation and hypersebaceous activity.
By: John Jesitus
Orlando, Fla. — Botulinum toxin type A (BoNTA) may provide a reasonable therapeutic option for some patients with rosacea, according to experts who spoke at the Orlando Dermatology meeting recently.
“It’s very important for us to be aware that we have a limited understanding of all that botulinum toxin A is doing within the skin,” says Erin Gilbert, M.D., Ph.D. “We have been using it for more than 15 years clinically for its cosmetic benefits, and we have not begun to address the potential therapeutic power of this drug.” Dr. Gilbert is assistant professor of dermatology at SUNY Downstate Medical Center, New York.
Related article: Neuromodulators may be effective therapy for psoriasis
Among skin diseases, she says, “We know that the etiology of rosacea is multifactorial. For most people, there’s a strong inflammatory component.” As a clinician and researcher, she adds, “I approach rosacea from the perspective of neuroinflammation. We know that neuropeptide genes are dysregulated in rosacea. One of the relevant peptides may be vasoactive intestinal protein (VIP) peptide, while calcitonin gene-related peptide (CGRP) appears to play a larger role. These are common themes that are seen across the board in neuroinflammatory disorders.”